1 - Personal interests
Regular Paid Consultancy Work
| Company | Area | Product | Amount of funds received* |
|---|
| Johnson and Johnson (Janssen) | Pulmonary hypertension | Bosentan, macitentan, epoprostenol, selexipag | C |
| MSD | Pulmonary hypertension | Riociguat | C |
| GSK | Asthma, COPD | Mepolizumab | B |
| Ferrer | Pulmonary hypertension | Treprostinil | B |
| Acceleron | Pulmonary hypertension | Sotatercept | C |
| Bayer | Pulmonary hypertension | Riociguat | B |
| AOP Orphan | Pulmonary hypertension | Treprostinil | B |
| Altavant | Pulmonary hypertension | Rodatristat | B |
| Shou Ti | Pulmonary hypertension | Pipeline | B |
| MorphogenIX | Pulmonary hypertension | Pipeline | B |
| Chiesi | Pulmonary hypertension, COPD | Pipeline | B |
| Astra Zeneca | Asthma | Benralizumab | C |
| Novartis | Asthma | Omalizumab | B |
| Sanofi | Asthma | Dupilumab | B |
Personal Benefits
None
Personal Travel Grants or expenses for conferences etc.
None
Shares in any Relevant Companies (excluding mutual funds)
None
2 - Non-Personal interests
| Company | Nature of Support | Amount of funds received* |
|---|
| Johnson and Johnson (Janssen) | Pulmonary hypertension translation research | D |
| MSD | Pulmonary hypertension translation research | D |
| Acceleron | Pulmonary hypertension translation research | D |
| Shou Ti | Pulmonary hypertension translation research | D |
3 - Other Interests that may be seen as potential conflicts
None
4 - Tobacco-Industry related Conflicts of Interests
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
*Funds Code Legend
| A | B | C | D |
|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
